danny3: imo it depends on the value of the IP to Janssen. If it is their IP of choice for getting Johnson&Johnson drugs into cells, that alone would be a huge contract. It would give PYC real value as an acquisition target.
At present, as I read it, PW and NW don't make a profit on their loan funded shares unless an acquisition is over 6.4c/share. If they want to benefit(via these shares) I would expect a near term offer would need to be well in excess of that level to be considered.
SoT
Ann: Core patent granted in Australia , page-18
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.5¢ |
Change
0.005(4.17%) |
Mkt cap ! $583.2M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 13.0¢ | 11.5¢ | $188.8K | 1.537M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 1280409 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 97499 | 3 |
View Market Depth
| Last trade - 15.02pm 04/09/2024 (20 minute delay) ? |
| PYC (ASX) Chart |